# US 2013/0259929 A1 · Use of a phosphopeptide able to block her3/p85 interaction for the treatment of her2 hyper-expressing tumours

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0259929 A1
- Document ID: US20130259929A1
- Status: Published application
- Kind: A1
- Application number: 13/877,450
- Filed: 2011-09-29
- Published: 2013-10-03
- Earliest claimed: 2010-10-04
- Inventors: Rita Falcioni; Valentina Folgiero; Selene Eleonora Di Carlo; Giulia Bon
- Web page: https://patentgrep.com/patent/US20130259929A1

## CPC

- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 38/1808: {Epidermal growth factor [EGF] urogastrone}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention concerns the use of a phosphopeptide able to block HER3/p85 interaction for the treatment of HER2 hyper-expressing tumours, such as, for example, metastatic mammary tumour, possibly in combination with other anti-tumour agents like, for example, trastuzumab

## Claims

### Claim 1

A medicament comprising a phosphopeptide consisting of sequence:
RDGGGPGGDpYAAMGACPA (SEQ ID NO: 1), or a nucleotide sequence encoding for said phosphopeptide or a vector comprising said nucleotide sequence.

### Claim 2

A medicament comprising a phosphopeptide consisting of the following sequence:
RDGGGPGGDpYAAMGACPA (SEQ ID NO: 1), or a nucleotide sequence encoding for said phosphopeptide or a vector comprising said nucleotide sequence, in an amount suitable for treatment of a tumour selected from the group consisting of a solid tumour, a primary or metastatic tumour, a HER2 and HER3 hyper-expressing and having elevated PI3K activity tumour or a primary or metastatic tumor, a tumour positive for BRAF oncogene expression, and a melanoma.

### Claim 3 (depends on 2)

The medicament according to claim 2, wherein the tumour is a mammary tumour.

### Claim 4 (depends on 1)

The medicament according to claim 1, wherein said phosphopeptide is conjugated with a tumour targeting peptide and/or with an antineoplastic.

### Claim 5

A pharmaceutical combination of a phosphopeptide consisting of sequence:
RDGGGPGGDpYAAMGACPA (SEQ ID NO: 1), or a nucleotide sequence encoding for said phosphopeptide or a vector comprising said nucleotide sequence, with one or more anti-tumour active principles.

### Claim 6 (depends on 5)

The pharmaceutical combination according to claim 5, wherein the anti-tumour active principles are selected from the group consisting of trastuzumab, Anthracyclines with or without docetaxel, Doxorubicin, Cyclophosphamide, Docetaxel, Carboplatin, Paclitaxel, Tamoxifene, humanized monoclonal antibody Bevacizumab, PLX4720, GSK2118436 or Farnesyl transferase inhibitor.

### Claim 7 (depends on 5)

The pharmaceutical combination of claim 5 formulated for simultaneous, separated or delayed use of said phosphopeptide, or nucleotide sequence or vector, and one or more anti-tumour active principles.

### Claim 8 (depends on 5, 6, 7)

The pharmaceutical combination of claims 5-7 formulated for treatment of a tumour selected from the group consisting of a solid tumour, a primary or metastatic tumour, a HER2 and HER3 hyper-expressing and having elevated PI3K activity tumour or primary or metastatic tumour, a tumour positive for BRAF oncogene expression, and a melanoma.

### Claim 9 (depends on 8)

The pharmaceutical combination according to claim 8, wherein the tumour is a mammary tumour.

### Claim 10

A pharmaceutical composition comprising a phosphopeptide consisting of sequence RDGGGPGGDpYAAMGACPA (SEQ ID NO: 1), or a nucleotide sequence encoding for said phosphopeptide or a vector comprising said nucleotide sequence alone or in combination with one or more anti-tumour active principles, as active principles, in combination with one or more pharmaceutically acceptable excipients and/or adjuvants.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the composition is in form of liposomes.

### Claim 12 (depends on 11)

The pharmaceutical composition according to claim 11, wherein the liposomes' membrane is conjugated with anti-tumour antibodies.

### Claim 13 (depends on 10)

The pharmaceutical composition according to claim 10 formulated for treatment of tumours selected from the group consisting of a solid tumour, a primary or metastatic tumour, a HER2 and HER3 hyper-expressing and having elevated PI3K activity tumour or a primary or metastatic tumour, a tumour positive for BRAF oncogene expression, and a melanoma.

### Claim 14 (depends on 13)

The pharmaceutical composition according to claim 13, wherein the tumour is a mammary tumour.

### Claim 15 (depends on 2)

The medicament according to claim 2, wherein said phosphopeptide is conjugated with tumour targeting peptides and/or with antineoplastics.

### Claim 16

A method to treat a medical condition of a patient, the method comprising
administering to the patient an effective amount of a phosphopeptide consisting of sequence RDGGGPGGDpYAAMGACPA (SEQ ID NO: 1), or a nucleotide sequence encoding for said phosphopeptide or a vector comprising said nucleotide sequence

### Claim 17

A method to treat a tumour in a patient the method comprising
administering to the patient a phosphopeptide consisting of sequence RDGGGPGGDpYAAMGACPA (SEQ ID NO: 1), or a nucleotide sequence encoding for said phosphopeptide or a vector comprising said nucleotide sequence, in an effective amount to treat a tumour selected from the group consisting of a solid tumour, a primary or metastatic tumour, a HER2 and HER3 hyper-expressing and having elevated PI3K activity tumour or a primary or metastatic tumor, a tumour positive for BRAF oncogene expression, and a melanomas.

### Claim 18 (depends on 17)

The method of claim 17, wherein the administering is performed in combination with one or more anti-tumour active principles.

### Claim 19 (depends on 17)

The method of claim 17, wherein the wherein the phosphopeptide is conjugated with tumour targeting peptides and/or with antineoplastics.

### Claim 20 (depends on 17)

The method of claim 17, wherein the tumour is a mammary tumour.
